Experimental cancer drug OMX-0407 trial halted early
NCT ID NCT05826600
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This early-phase trial tested OMX-0407, a new drug that blocks certain enzymes, in 68 adults with advanced solid tumors that had stopped responding to other treatments. The study aimed to find a safe dose and check if the drug could shrink tumors. However, the trial was terminated before completion, so we have limited information on its safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OMX-0407 (a salt-inducible kinase inhibitor)
- What this could lead to
- If successful, this could point toward a new treatment option for certain advanced solid tumors like kidney or lung cancer.
- What could go wrong
- The trial was terminated early, so results are limited. It was a small, early-phase study, and the drug may not prove effective or safe in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique Hopitaux de Marseille- Hopital de La Timone
Marseille, France
-
CHU de Liège
Liège, 4000, Belgium
-
CHU de Toulouse
Toulouse, France
-
Centro Integral Oncológico Clara Campal
Madrid, 28050, Spain
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Clínica Universidad de Navarra
Madrid, 28027, Spain
-
Clínica Universidad de Navarra
Pamplona, 31008, Spain
-
Gustave Roussy - Institut Gustave Roussy
Paris, France
-
Hospital La Fe de Valencia
Valencia, 46026, Spain
-
Hospital Universitario Gregorio Marañon
Madrid, 28007, Spain
-
Hospital Universitario Vall d'Hebrón
Barcelona, 08035, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
ICO Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08906, Spain
-
Institut de Cancerologie de Ouest (ICO) - Saint-Herblain
Nantes, France
-
Institut du Cancer Montpellier (ICM)
Montpellier, France
-
MD Anderson Cancer Center
Madrid, 28033, Spain
-
NEXT Oncology - Hospital Quironsalud Barcelona
Barcelona, Spain
-
NEXT Oncology - Hospital Universitario Quironsalud
Madrid, Spain
-
START Madrid - Hospital Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
UNICANCER - Centre Oscar Lambret
Nantes, France
-
UNICANCER-Institut Bergonie - Nouvelle-Aquitaine
Bordeaux, France
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Universite de Lyon - Centre Leon-Berard (CLB)
Lyon, France
-
ZAS Augustinus Afdeling Oncologische Research
Wilrijk, 2610, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a new infusion drug tame advanced solid tumors?
- Can a radioactive injection target bone tumors? a Dose-Finding trial aims to find out
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?